Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05466318 | ChiCGB vs BEAM in High-risk or R/R Lymphomas | unknown | Phase 3 | 306 | Sichuan UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05458180 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL |
| unknown |
| Phase 1 / Phase 2 |
| 60 |
| Peking Union Medical College HospitalOTHER |
| 1 |
| Jul 1, 2022 |
| clinicaltrials |
| NCT05426824 | The Whole-course Management of Pegaspargase in ENKTL | unknown | N/A | 72 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05398614 | SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies | unknown | Phase 1 | 18 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04928105 | Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma | unknown | N/A | 100 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | May 31, 2022 | clinicaltrials |
| NCT05387226 | Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma | unknown | Phase 1 | 6 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | May 24, 2022 | clinicaltrials |
| NCT03671850 | VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | unknown | Phase 2 | 48 | ViGenCell Inc.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03853044 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04480125 | Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | unknown | Phase 2 | 28 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04491825 | Diagnostic Classifier for Cutaneous T-cell Lymphomas | unknown | — | 160 | Medical University of ViennaOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03646422 | AEDV Registry of Primary Cutaneous Lymphoma | unknown | — | 2,000 | Fundación Academia Española de DermatologíaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04823091 | Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies | unknown | Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Feb 14, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05206045 | Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies(SURPASSe) | unknown | — | 700 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05179213 | Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03629873 | Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects | unknown | Phase 2 | 69 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05149170 | Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05127135 | Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | unknown | Phase 1 | 30 | Fundamenta Therapeutics, Ltd.INDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT05059912 | CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03439501 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | unknown | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT02631239 | MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma | unknown | Phase 3 | 256 | Ruijin HospitalOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04999878 | A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.(RUE-DDGP) | unknown | Phase 4 | 30 | Zhengzhou UniversityOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04264078 | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04934774 | Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances | unknown | Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04917250 | GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 15 | Beijing Tongren HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04899414 | Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma | unknown | Phase 2 | 50 | Peking UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04162340 | CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies | unknown | Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | May 19, 2021 | clinicaltrials |
| NCT04880746 | Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study | unknown | Phase 3 | 266 | Ruijin HospitalOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT04831710 | Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL | unknown | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04319601 | Rituximab Combined With Chidamide and Lenalidomide for r/r AITL(AITL) | unknown | N/A | 26 | Zhejiang Cancer HospitalOTHER | 1 | Mar 24, 2021 | clinicaltrials |
| NCT02085655 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | unknown | Phase 3 | 264 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04052659 | Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL | unknown | Phase 2 | 30 | Peking UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT04785833 | CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia | unknown | N/A | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT03502629 | Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) | unknown | Phase 2 | 86 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04594135 | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies(CD5CAR-T) | unknown | Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04705090 | A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma | unknown | Phase 2 | 90 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 12, 2021 | clinicaltrials |
| NCT04480788 | CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study | unknown | Phase 1 | 9 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04696705 | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | unknown | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04679506 | the Efficacy and Safety of CLAE in R/R T-ALL/LBL | unknown | — | 50 | Peking University Third HospitalOTHER | 0 | Dec 22, 2020 | clinicaltrials |
| NCT04676789 | Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL(SPENT) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04489264 | The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma | unknown | — | 60 | Peking UniversityOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04620655 | RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL | unknown | N/A | 24 | Min XiangOTHER | 1 | Nov 9, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jul 25, 2022source: clinicaltrials